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The brain is the most cholesterol-rich organ in the
body, most of which comes from in situ synthesis.
Herewedemonstrate that in insulin-deficient diabetic
mice, there is a reduction in expression of the major
transcriptional regulator of cholesterol metabolism,
SREBP-2, and its downstream genes in the hypothal-
amus and other areas of the brain, leading to a reduc-
tion in brain cholesterol synthesis and synaptosomal
cholesterol content. These changes are due, at least
in part, to direct effects of insulin to regulate these
genes in neurons and glial cells and can be corrected
by intracerebroventricular injections of insulin.
Knockdown of SREBP-2 in cultured neurons causes
a decrease in markers of synapse formation and
reduction of SREBP-2 in the hypothalamus of mice
using shRNA results in increased feeding and weight
gain. Thus, insulin and diabetes can alter brain
cholesterol metabolism, and this may play an impor-
tant role in the neurologic and metabolic dysfunction
observed in diabetes and other disease states.
INTRODUCTION
Both type 1 (insulin-dependent) and type 2 (insulin-resistant)
diabetes are associated with hyperglycemia; alterations in
carbohydrate, lipid, and protein metabolism; and a variety of
complications affecting tissues of the body. These complica-
tions extend to the central nervous system (CNS), where they
range from acute alterations in mental status due to poor meta-
bolic control to greater rates of decline in cognitive function with
age (Biessels et al., 2008; Cukierman et al., 2005), higher preva-
lence of depression (Ali et al., 2006), and an increased risk of Alz-
heimer’s disease (Craft and Watson, 2004).
The brain is themost cholesterol-rich organ, containing approx-
imately 25% of the cholesterol present in the body. Almost all
cholesterol present in the brain is formed by de novo synthesis,
since the blood-brain barrier effectively prevents uptake from theCell Mcirculation (Bjo¨rkhem and Meaney, 2004; Dietschy and Turley,
2004).Mutations ingenes regulatingcholesterolmetabolism result
in several hereditary syndromes showing CNS manifestations,
including Niemann-Pick Disease Type C and Smith-Lemli-Opitz
syndrome (Korade and Kenworthy, 2008). The pathogenesis of
Alzheimer’s disease is also linked to brain cholesterol metabolism
with genetic risk factors including variations in apolipoprotein
E and other cholesterol-related genes (Puglielli et al., 2003; Sho-
bab et al., 2005). Cholesterol metabolism in the brain plays an
important role in myelin production (Dietschy and Turley, 2004)
and has been implicated in regulation of many processes,
including the synaptophysin/synaptobrevin interaction (Mitter
et al., 2003) and geranylgeraniol production (Kotti et al., 2006).
A number of abnormalities have been reported in mouse
models of diabetes, including alterations in learning, memory,
synaptic plasticity, and glutamatergic neurotransmission (Bies-
sels and Gispen, 2005). Some of these appear to be the result
of direct effects of insulin, which is transported into the CNS
across the blood-brain barrier by a receptor-mediated transport
process (Banks et al., 1997), as well as access of insulin to brain
areas where the blood-brain barrier is less tight. Mice with
heterozygous knockout of the insulin receptor exhibit impair-
ment in object recognition (Das et al., 2005). Intranasal insulin
administration can improve cognitive function in diabetic (Fran-
cis et al., 2008) and nondiabetic mice (Marks et al., 2009) without
significant alterations in blood glucose levels.
Despite the accumulated evidence indicating effects of dia-
betes and insulin on neuronal function, the molecular mecha-
nisms underlying the cerebral complications of diabetes have
been yet to be elucidated. In the present study we show that
diabetes produces a global suppression of the enzymes of
cholesterol synthesis and their master transcriptional regulator
SREBP-2 in the brain, and this results in reduced cholesterol
biosynthesis, reduced synaptosomal membrane cholesterol,
and altered neuronal and physiological function.
RESULTS
Downregulation of the Cholesterol Biosynthesis
Pathway in Hypothalami of Diabetic Mice
The hypothalamus is a major point of control of the endocrine
system, appetite, and energy balance (Obici and Rossetti,etabolism 12, 567–579, December 1, 2010 ª2010 Elsevier Inc. 567
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lamic function, we used oligonucleotide microarrays to identify
genesdifferentially expressed in the hypothalamus in the strepto-
zotocin (STZ)-induced diabetic mice (a model of insulin-deficient
type 1 diabetes). Gene set enrichment analysis (GSEA) indicated
the cholesterol biosynthesis pathway as one of the most highly
regulated gene sets in the hypothalamus of the STZ-diabetic
mouse, with a broad decrease in expression of multiple choles-
terologenic genes (Figure S1). Quantitative real-time PCR
(qPCR) confirmed significant decreases in the majority of the
genes encoding enzymes in the pathway producing cholesterol,
including a 26%decrease in the rate-limiting enzyme 3-hydroxy-
3-methylglutaryl-CoA reductase (Hmgcr) and decreases in
mRNA for other cholesterologenic enzymes ranging from
7%–36%. All changes in cholesterologenic genes were reversed
by insulin treatment of the diabetic mice (Figure 1A).
Cellular cholesterol and fatty acid homeostasis is transcrip-
tionally regulated by three members of sterol regulatory
element-binding protein (SREBP) family: SREBP-1a, SREBP-1c,
and SREBP-2. Of these, SREBP-2 preferentially activates genes
responsible for cholesterol synthesis (Horton et al., 2002). By
qPCR, SREBP-2 (Srebf2) was downregulated by 34% in the
STZ-diabetic mice. The expression level of SREBP-1a (Srebf1a)
was also slightly, but significantly, reduced in the STZ hypothal-
amus, whereas SREBP-1c (Srebf1c) expression was unaffected
(Figure 1B). Western blotting of hypothalamic extracts revealed
that the nuclear mature form of SREBP-2 protein, i.e., transcrip-
tionally active form, was also decreased (Figure 1C). Consistent
with the mRNA data, protein levels of HMGCR, farnesyl diphos-
phate synthase (FDPS), and squalene epoxidase (SQLE), as well
as those of the cytoplasmic precursor form of SREBP-2, were
decreased as assessed by Western blotting (Figure 1D).
Cholesterol Synthesis Pathway Is Suppressed in Other
Diabetes Models and throughout the Brain
A reduction in cholesterol synthetic enzymes at the mRNA level
was observed in multiple other diabetes models in which insulin
levels were reduced. Thus, Srebf2 and its downstream genes
were downregulated by 30% in the hypothalami from nonob-
ese diabetic (NOD) mice, an autoimmune model of type 1 dia-
betes (Figure 2A), and hypothalami from obese, insulin-resistant
db/dbmice on aC57Bl/Ks background (Figure 2B), which exhibit
a combination of obesity, insulin resistance, and declining insulin
levels due to progressive b-cell failure (Uchida et al., 2005). By
contrast, hypothalami of mice with dietary-induced (DIO) and
genetic obesity (ob/ob), which have insulin resistance without
loss of insulin secretion and milder degrees of hyperglycemia,
showed no alteration in expression of these genes by microarray
analysis (Figure S1) or qPCR (Figures S2A and S2B). These
results suggest that absolute or relative decreases in circulating
insulin levels and/or the degree of hyperglycemia, but not obesity
or systemic insulin resistance, cause suppression of SREBP-2
and cholesterol synthesis pathway in the brain. Consistent with
a role for insulin in SREBP-2 regulation in brain, fasting for
24 hr, which results in a decrease in both insulin and glucose,
also caused downregulation of Srebf2 and cholesterol synthetic
genes in mouse hypothalami similar to that seen in STZ-diabetic
mice (Figures 2C and S2C). Srebf2 was also significantly down-
regulated in the hypothalami of NIRKO mice with brain-specific568 Cell Metabolism 12, 567–579, December 1, 2010 ª2010 Elsevierinsulin receptor knockout (Bru¨ning et al., 2000), and in this
model, there was no further reduction by fasting, consistent
with insulin being one of the factors regulating Srebf2 expression
in the CNS (Figure 2C).
Downregulation of SREBP-2 and cholesterologenic genes due
to diabetes is not limited to the hypothalamus, but part of a more
general effect on the brain. In the cerebral cortex, STZ-induced
diabetes produced a robust reduction of these cholesterolo-
genic genes with a 36% decrease in Srebf2 mRNA and a 38%
decrease in Hmgcr mRNA (Figure 2D). As with the hypothal-
amus, these were associated with parallel changes in the protein
levels encoded by these transcripts in the cerebral cortex
(Figure 2E).
Role of Insulin Versus Hyperglycemia in Control
of the Cholesterol Synthesis
To determine whether hyperglycemia or insulin insufficiency was
responsible for the suppression of cholesterol synthesis
pathway in the diabetic mouse brain, we treated the STZ-
induced diabetic mice with phlorizin (PHZ), a flavonoid that can
decrease blood glucose levels by inhibition of renal glucose
transport without restoring insulin secretion (Rossetti et al.,
1987). As shown in Figure 3A (right), PHZ treatment efficiently
normalized hyperglycemia in the STZ-diabetic mice to a level
similar to that seen with insulin treatment. This reduction of blood
glucose did not reverse suppression of SREBP-2 and its down-
stream genes in the hypothalamus of diabetic mice (Figure 3A,
left panel), suggesting that hyperglycemia is not the major driver
for the suppression of cholesterol synthesis in diabetes.
To assess the effects of insulin, we directly administered
insulin into the cerebral ventricles of STZ-induced diabetic
mice by three injections of insulin into a catheter placed in the
lateral ventricle. This intracerebroventricular (ICV) injection of
insulin did not affect blood glucose levels (Figure 3B, right).
However, the suppression of SREBP-2 pathway in the hypothal-
amus of the diabetic mouse was almost completely normalized
by insulin ICV injection (Figure 3B, left), indicating that insulin
deficiency is a major cause of the suppression. ICV injection of
insulin also partially normalized the expression the neuropep-
tides expression involved in feeding behavior (proopiomelano-
cortin [Pomc], agouti-related peptide [Agrp], and neuropeptide
Y [Npy]), and partly reversed the hyperphagia induced by STZ
diabetes (Figure 3C). Together, these data indicate that insulin
deficiency, not hyperglycemia, is the major driver of the altered
cholesterol biosynthesis observed in the diabetic mouse.
Decreased Cholesterol Synthesis in the Diabetic Brain
Is AccompaniedbyDecreasedSynaptosomalMembrane
Cholesterol
To determine if these changes in cholesterologenic gene expres-
sion in diabetes affected brain cholesterol synthesis, we directly
assessed cholesterol synthesis in STZ-diabetic and control mice
using tritiated water (Figure 4A, left panel). In vivo cholesterol
synthesis in the brain was reduced by 24% (p < 0.05) in diabetic
mice (Figure 4A, right panel), closely paralleling the decrease in
cholesterologenic enzymes. Since much of brain cholesterol is
in slowing turning over myelin (Dietschy and Turley, 2004), it is
not surprising that no change was observed in total cholesterol
content in the cerebral cortex after only 18 days of diabetesInc.
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Figure 1. Cholesterol Synthetic Genes are Broadly Suppressed in the Diabetic Hypothalamus
(A) Comparison of gene expression for the cholesterol synthetic enzymes in hypothalami of control (CON, n = 6), STZ-diabetic (STZ, n = 5), and insulin-treated STZ
(STZ + INS, n = 7) mice. Hypothalami were collected frommale C57Bl/6 mice 9 days after STZ injection. Expression wasmeasure by qPCR, and average values in
CON assigned a value of 1. Bars denote mean ± SEM; a, p < 0.01 between CON and STZ; b, p < 0.01 between STZ and STZ+INS by ANOVA. The lower panel
shows a schematic of the cholesterol-synthesis pathway.
(B) Expression levels of SREBP isoforms in the hypothalamus normalized for Tbp.
(C) Western blots of nuclear extracts from hypothalami of control and STZ-diabetic mice for nuclear SREBP (nSREBP) indicated by arrows. Lamin is an internal
control.
(D) Densitometry of the Western blots for SREBP precursors (pSREBP) and other proteins. Cytoplasmic extracts were used. Values are normalized by actin as
a control. *p < 0.05; **p < 0.01; ***p < 0.001 by ANOVA (B) or t test (D).
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Figure 2. Diabetes, Fasting, and Insulin
Regulation of Cholesterol-Synthetic Genes
in the Brain
(A) Comparison of the major cholesterologenic
genes and Srebf2 gene expression in 5-month-
old prediabetic NOD (n = 6) and diabetic NOD
(n = 5) mouse hypothalami was performed by
qPCR.
(B) Gene expression in hypothalami of 9-week-old
control db/+ (n = 6) and obese diabetic db/db
(n = 6) mice on a C57Bl/Ks background was as-
sessed by qPCR.
(C) The effects of 24 hr fasting and brain-insulin
receptor ablation on gene expression in the hypo-
thalamus (n = 7 in each group). Average expres-
sion values in fed control hypothalami were as-
signed a value of 1.
(D) Gene expression in the cerebral cortices of
STZ-diabetic mice was measured by qPCR.
(E) Densitometry of Western blots for cholesterol
synthetic enzymes in the STZ-diabetic cerebral
cortex. Values were normalized using actin as an
internal control. *p < 0.05; **p < 0.01;
***p < 0.001 by t test (A and B) or ANOVA (C–E).
Error bars represent SEM.
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Insulin Regulates Brain Cholesterol Metabolism(13.7 ± 0.4 versus 14.1 ± 0.4 mg/g of tissue:, p = 0.49). However,
the reduced cholesterol synthesiswas reflectedwith a significant
and parallel 22% decrease in cholesterol content of isolated
synaptosomal membranes from the brains of diabetic mice
(Figure 4B).
As noted above, alterations in brain cholesterol in humans
have been suggested to play a role in some neurological and
neurodegenerative diseases. To determine if these cholesterol
synthetic processes might be regulated in humans, we analyzed
cholesterol synthetic gene-expression patterns and synapto-
somal cholesterol content in cerebral cortices from 16 elderly
(75–99 years old) humans. In the cortices, there was a strong
positive correlation between the levels of Srebf2 mRNA and
those for two of its downstream targets—Hmgcr and Fdps (Fig-
ure S3A). More importantly, there was a significant positive
correlation (r = 0.58, p = 0.02) between cholesterol content in iso-
lated synaptosomal membranes and the mRNA expression of
Fdps, (Figure S3B), suggesting that factors that control expres-570 Cell Metabolism 12, 567–579, December 1, 2010 ª2010 Elsevier Inc.sion of genes for cholesterol synthesis
may also affect synaptosomal cholesterol
in human brains.
Broad suppression of the cholesterolo-
genic pathway in diabetes affects
multiple steps of cholesterol biosynthesis
in the brain. Thus, cholesterol precursors,
such as desmosterol, lathosterol, and
lanosterol, were reduced by 26%, 44%,
and 60%, respectively, in the brain of
STZ-induced diabetic mice (Figure 4C).
Thus, in addition to its effects on choles-
terol synthesis, diabetes may suppress
synthesis of other related lipid products,
including isoprenoids, dolichols, and
ubiquinone in the brain.Cholesterol in the brain can be converted to 24-hydroxycho-
lesterol, which can spontaneously diffuse into the circulation,
by a neuronal enzyme cholesterol 24-hydroxylase (CYP46A1)
(Russell et al., 2009). Interestingly, although the expression of
CYP46A1 was mildly downregulated (Figure S3C), the content
of 24-hydroxycholesterol in the STZ-diabetic brain was slightly
increased (12%) (Figure 4C). Content of other oxysterols, such
as 24,25-epoxycholesterol and 27-hydroxycholesterol, on the
other hand, was decreased (Figure 4C).
Insulin Activates Cholesterol Biosynthesis Pathway
in Cultured Neurons and Glial Cells
To dissect the cell type and factors regulating the changes in
cholesterol biosynthesis, we isolated and cultured neuron and
glial cells (astrocytes) from the cortices of 16-day-old C57Bl/6
mouse embryos and 1-day-old neonates, respectively. In both
cell types, 6 hr of exposure to insulin (10–100 nM) stimulated
expression of all of the cholesterologenic genes by 30%–270%
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Figure 3. Reduction of Hyperglycemia Does Not Reverse Suppression of the SREBP-2 Pathway, Whereas Intracerebroventricular (ICV)
Insulin Does
(A) C57Bl/6 mice received injection of phlorizin (PHZ) or vehicle (VEH) solution twice daily for 10 days from day 8 after the STZ treatment. In the left panel, compar-
ison of gene expression for Srebf2 and its major downstream genes in hypothalami of VEH-treated control (CON+VEH, n = 5), VEH-treated STZ-diabetic
(STZ+VEH, n = 6), and PHZ-treated STZ (STZ+PHZ, n = 5) mouse hypothalami was performed by qPCR. In the right panel, blood glucose levels were measured.
a, p < 0.05 between CON+VEH and STZ+VEH; b, p < 0.05 between STZ + VEH and STZ + PHZ by ANOVA.
(B) STZ-diabetic mice received ICV injections of insulin or vehicle as described in Experimental Procedures. Left panel: Gene expression in hypothalami of
vehicle-injected control (CON+VEH icv, n = 4), vehicle-injected STZ-diabetic (STZ+VEH icv, n = 5), and insulin-injected STZ (STZ+INS icv, n = 4) mouse
hypothalami was assessed by qPCR. Right panel: Blood glucose levels were measured 4 hr after the last ICV injection. a, p < 0.05 between CON + VEH icv
and STZ + VEH icv; b, p < 0.05 between STZ + VEH icv and STZ + PHZ icv by ANOVA.
(C) The effects of the insulin ICV injection on feeding behavior and neuropeptide gene expression were monitored. Comparison of gene expression for neuro-
peptides regulating appetite was performed by qPCR (left). Food intake was measured after the ICV injection (right). Error bars represent SEM.
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Insulin Regulates Brain Cholesterol Metabolism(Figure 5A). Incubation of cells with high concentrations (25 mM)
of glucose for 3 days suppressed mRNA of some cholesterolo-
genic genes, such as Sqle and Fdps, in glial cells, but had no
effect on any of the cholesterologenic genes in cortical neurons
(Figure 5B), consistent with the in vivo studies (Figure 3A) sug-
gesting that insulin, not hyperglycemia, is responsible for theCell Maltered expression of genes involved in cholesterol synthesis in
brain in diabetes.
Effects of insulin on cholesterol synthetic genes involve
multiple signaling pathways. In liver, SREBP effects on lipogen-
esis involve Akt, atypical protein kinase C, and mTORC1 activity
(Li et al., 2010; Porstmann et al., 2008; Taniguchi et al., 2006). Inetabolism 12, 567–579, December 1, 2010 ª2010 Elsevier Inc. 571
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Figure 4. Diabetes Suppresses Cholesterol
Synthesis and Reduces Cholesterol
Content in Synaptosomal Membranes
(A) In vivo cholesterol synthesis in the whole
cerebra was assessed for control (n = 4) and
STZ-diabetic (n = 4)mice 17 days after STZ admin-
istration using the protocol shown on the left.
Cerebra were dissected 1 hr after intraperitoneal
injection of tritiated water, and cholesterol was
isolated by thin layer chromatography (TLC) from
the extracted lipid. In the right panel, the rate of
cholesterol synthesis is expressed as nmol
cholesterol synthesized per gram of cerebrum
per hour.
(B) Cholesterol content in the synaptosomal
membrane extracted from the frontal cortex of
control (n = 4) and STZ-diabetic (n = 4) mice
18 days after STZ administration. Synaptosome-
rich fraction was separated from myelin fraction
by discontinuous sucrose gradient centrifugation
as shown on the left (Kolomiytseva et al., 2008).
The synaptosomal cholesterol content in mg per
mg protein is shown on the right.
(C) Content of representative sterols in the brain
measured by HPLC/MS (McDonald et al., 2007)
for control (n = 4) and STZ-diabetic (n = 4) mice
18 days after STZ injection. 24-OH-chol, 24-hy-
droxycholesterol; 24,25-ep-chol, 24,25-epoxy-
cholesterol; 27-OH-chol, 27-hydroxycholesterol.
*p < 0.05; ***p < 0.001 by t test. Error bars repre-
sent SEM.
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Insulin Regulates Brain Cholesterol Metabolismcultured glia, rapamycin, as well as the PI3-kinase inhibitor
LY294002 and the MEK inhibitor U0126, partially suppressed
insulin’s effect on Hmgcr induction, and these effects were addi-
tive, suggesting that the mTORC1, PI 3-kinase, and MAP-kinase
pathways act together inHmgcr induction by insulin (Figure S4A).
Treatment of cultured glia with the glycogen synthase
kinase (GSK) 3 inhibitor SB216763 mimicked insulin’s effects
on this pathway producing a broad increase in expression of
cholesterol synthetic genes that was also inhibited by pretreat-572 Cell Metabolism 12, 567–579, December 1, 2010 ª2010 Elsevier Inc.ment of cells with the mTORC1 inhibitor
rapamycin (Figure S4B). Since the
mTORC1 pathway is activated by nutri-
ents (Avruch et al., 2009), as well as
hormones like insulin, this pathway may
play a role in the decrease of cholesterol
synthetic genes induced by fasting
(Figure S2C).
Loss of SREBP-2 Reduces
Pre- and Postsynaptic Markers
in Hippocampus Neurons
Cholesterol is crucial for synaptic struc-
ture, function, and genesis (Mauch
et al., 2001). To investigate the effects of
reduced cholesterologenic genes in
brain, we generated an SREBP-2
silencing lentivirus vector (Lenti-
shSREBP2), which coexpressed Srebf2
shRNA with green fluorescent protein(GFP) under the control of cytomegalovirus promoter (Figure 6A).
Western blot analysis indicated that the infection with Lenti-
shSREBP2 vector suppressed SREBP-2 expression by 90% in
N25/2 mouse hypothalamic neuronal cells in culture compared
with a control nonsilencing vector (Figure 6B). Transient infection
with the Lenti-shSREBP2 without selection caused 60% reduc-
tion of Srebf2 and Hmgcr genes in primary cultured mouse
hippocampal neurons (Figure 6C). This resulted in an 40%
reduction (p < 0.001) in density of synapse formation on the
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Figure 5. Insulin Induces Cholesterol
Synthetic Gene Expression in Mouse
Primary Cultured Glia and Neurons
(A) Primary mouse cultured cortical neurons and
glia (18 days in vitro) were incubated in medium
with insulin for 6 hr. Data are representative of
three experiments.
(B) Primary culture cortical neurons and glia were
incubated with low (5 mM) or high (25 mM)
concentrations of glucose in medium for 72 hr. In
all panels, mRNA was extracted from the cells at
the end of treatment and gene expression levels
were quantified by qPCR. *p < 0.05; **p < 0.01;
***p < 0.001 by ANOVA. Error bars represent SEM.
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Insulin Regulates Brain Cholesterol Metabolismneurites as indicated by staining with the postsynaptic marker
PSD95 (Figure 6D). In the SREBP2 knockdown neurites, there
was also a 34% decrease in the staining intensity of the synaptic
vesicle marker VAMP2 (Figure 6E), consistent with the role of
cholesterol in synaptic vesicle biogenesis (Thiele et al., 2000)
and exocytosis (Lang et al., 2001). These findings provide
a link between diabetes and altered synapse function and help
explain the reports of decreased synaptic markers in hippo-
campus and cortex of STZ-diabetic mice (Francis et al., 2008).
SREBP-2 Knockdown in the Hypothalamus Affects
Feeding Behavior and Endocrine Homeostasis
To begin to elucidate the physiological role of SREBP-2 in the
brain in vivo, we injected the Lenti-shSREBP2 vector directly
into the hypothalami of C57Bl/6 mice. This produced a 33%
reduction in the precursor and 44% reduction in the nuclear
forms of SREBP-2 in the ventral hypothalamus (Figure 7A).
GFP fluorescence, an indicator of lentivirus infection, was
observed in neuronal cell bodies and some astrocyte processes
(Figure 7B) in the paraventricular hypothalamus (PVH), ventro-
medial hypothalamus (VMH), and arcuate nucleus (ARC) (Fig-
ure S5A). After a brief initial decline in food intake in all mice
receiving intrahypothalamic injection, mice with knockdown of
SREBP-2 exhibited a 14% increase in nocturnal food intake
(p < 0.01) and a similar increase in total daily food intake (Figures
7C and S5B). As a result, body weight gain over the 21 daysCell Metabolism 12, 567–579,following injection was significantly
greater in the mice treated with Lenti-
shSREBP2 compared to controls (Fig-
ures 7D and 7E). Neurons in the VMH
are largely glutamatergic (Tong et al.,
2007) and have been shown to mediate
counterregulatory responses to hypogly-
cemia (Borg et al., 1994). In this regard,
mice with hypothalamic knockdown of
SREBP-2 exhibited a 34% reduction of
circulating norepinephrine (Figure 7F)
and glucagon (Figure S5C) in the fasted
state and a small increase in fasting
insulin levels (Figure 7G). Insulin tolerance
tests (Figure S5D) and glucose tolerance
testing (Figure S5E) showed either no
change or a very modest improvement,
and there was no change in physicalactivity or whole body oxygen consumption rate as assessed
in metabolic cages (Figure S5F).
DISCUSSION
The brain is the most cholesterol-rich organ in the body, most of
which comes from in situ synthesis (Dietschy and Turley, 2001).
Brain cholesterol turnover is increased in Alzheimer’s and other
neurodegenerative diseases, and has been suggested to play
a role in pathogenesis of these disorders (Reiss et al., 2004). Dia-
betesmellitus is associatedwith a variety of neurologic and cere-
bral complications, including cognitive dysfunction, depression,
and increased risk of Alzheimer’s disease (Biessels et al., 2008;
Craft and Watson, 2004; Cukierman et al., 2005). In this study,
we show that the cholesterol biosynthesis pathway is downregu-
lated in hypothalami and cortices of STZ-diabetic mice, as well
as other insulin-deficient diabetic models. This change in gene
expression leads to a decrease in cholesterol synthesis in brain
and a decrease in cholesterol content in synaptosomal
membranes. Mimicking the reduction in cholesterologenic
genes in cultured neurons by knockdown of SREBP-2 results
in reduced markers of synapse formation, and knockdown of
SREBP-2 in the hypothalamus in vivo causes altered feeding
behavior and dysregulation of counterinsulin hormones.
The notion of decreased cholesterol biosynthesis leading to
altered brain function is supported by in vitro studies that haveDecember 1, 2010 ª2010 Elsevier Inc. 573
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Figure 6. SREBP-2 Silencing Lentivirus
Vector Reduces Synaptic Marker Staining
in Dendrites of Hippocampal Neurons
(A) Schematic of the pGIPZ-shSREBP2 construct.
pCMV, cytomegalovirus promoter; GFP, green
fluorescent protein; IRES, internal ribosome entry
site; PuroR, puromycin resistance gene; LTR,
long terminal repeat; SIN-LTR, self-inactivating
LTR.
(B) Western blots of murine hypothalamic neuronal
N-25/2 cells with control nonsilencing (NS) and
shSREBP2 lentivirus infection.
(C) Expression levels of Srebf2 and Hmgcr in the
primary cultured mouse hippocampal neurons
after the lentivirus infection. Values were normal-
ized for Tbp expression.
(D) Postsynaptic marker staining in primary
cultured mouse hippocampal neurons (8 days
in vitro) after lentivirus-mediated SREBP-2
silencing. Left panels show representative
confocal images. Red represents PSD95, green
derives from GFP that the vectors encode, and
blue represents the neuron marker MAP2. In right
panel, PSD95 density in neurites was calculated
as signal-positive area divided by the length of
neurite. Values were measured in 69 neurites
from 30 neurons (Lenti-NS) and 78 neurites from
27 neurons (Lenti-shSREBP2) using ImageJ soft-
ware. Scale bar, 25 mm.
(E) Staining for the synaptic vesicle marker VAMP2
in the hippocampal neurons. In the left two images,
red represents VAMP2, and the other colors are as
above. In the right panel, average VAMP2 staining
intensity in the neurites has been calculated using
65 neurites from 35 neurons for the Lenti-NS:
control and 49 neurites from 20 neurons for the
Lenti-shSREBP2 infected cells. Data are repre-
sentative of three independent experiments.
***p < 0.001 by t test. Error bars represent SEM.
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Insulin Regulates Brain Cholesterol Metabolismindicated that cholesterol is essential for synaptogenesis and
synapse function. For example, it has been shown that pharma-
cological depletion of cholesterol from lipid rafts in cultured
neuronal cells leads to gradual loss of synapses (Hering et al.,
2003). Depletion of cholesterol also has been shown to block
the biogenesis of synaptic vesicles (Rohrbough and Broadie,
2005; Thiele et al., 2000), and disrupt SNARE clusters leading
to decreased neurotransmitter release (Chamberlain et al.,
2001; Lang et al., 2001). Thus, the reduction in synaptosomal
membrane cholesterol observed in diabetes could contribute
to the glutamatergic synapse dysfunction and altered long-
term potentiation observed in the brains of diabetic animals (Tru-
deau et al., 2004). In addition, the reduction of specific synaptic
components, such as the scaffold protein PSD95, which is
decreased in neurons with reduced SREBP-2, could contribute
to reduced excitatory synapse formation and altered glutamate
release (El-Husseini et al., 2000).
The finding of unchanged total brain cholesterol versus
reduced synaptosomal membrane cholesterol content in the
acute diabetes model is not surprising. The majority (70%) of
cholesterol present in the CNS is in myelin sheaths and turns
over very slowly (Barres, 2008). Most of the remainder is in the574 Cell Metabolism 12, 567–579, December 1, 2010 ª2010 Elseviermembranes of astrocytes and neurons (Bjo¨rkhem and Meaney,
2004). This pool turns over more quickly (Okabe et al., 1999)
and is therefore likely to bemost reflective of short-term changes
in cholesterol synthesis. Impairment of myelin formation has
been observed in the brains of mouse models of long-term
type 1 diabetes (Francis et al., 2008). Reduced cholesterol
content in cortical synaptosomes and microsomes is also
observed in the Yakutian ground squirrel during hibernation
(Kolomiytseva et al., 2008). Our findings suggest that the hypoin-
sulinemia induced by prolonged starvation during hibernation
could lead to downregulation of SREBP-2 in brain resulting in
these changes.
Previous studies have suggested that, in the adult, neurons
rely on delivery of cholesterol from nearby astrocytes. This
‘‘outsourcing’’ allows the neurons to focus on generation of elec-
trical activity and dispense with energetically costly cholesterol
synthesis (Pfrieger, 2003). Our in vitro data, however, indicate
that insulin induces robust increases cholesterologenic gene
expression in both astrocytes and neurons. Thus, it appears
that both of these cell types participate in insulin-regulated
cholesterol synthesis and synapse maintenance (see Figure 7H),
and it is likely that both are altered in hypoinsulinemic diabetes.Inc.
Insulin
Cholesterol
transport
Synapse malfunction
Behavioral changes
– Cognitive decline?
– Feeding patterns
-cell
Neuron
GSK3
mTORC1
Akt
PI3K
MAPK
Cholesterol
synthesis
SREBP-2
mRNA
SREBP-2
activity
VAMP2
Endocrine dysregulation
– Counterregulatory response
Astroglia
GSK3mTORC1
Akt
PI3K
MAPK
Cholesterol
synthesis
SREBP-2
activity
GlutamateNMDAreceptor
PSD95
Synapse
Cholesterol
nSREBP-2
pSREBP-2
Actin
Lenti-
NS
Lenti-
shSREBP2
Lamin
M
A
P
2
G
F
P
D
A
P
I
G
F
A
P
G
F
P
D
A
P
I
Av
er
ag
e 
fo
od
 in
ta
ke
 (g
/d
ay
) Lenti-NS
Lenti-shSREBP2
1.8
2.0
2.2
2.4
2.6
2.8
3.0
3.2
Dark Total
**
* Lenti-NS
Lenti-shSREBP2
21.5
22.0
22.5
23.0
23.5
24.0
24.5
25.0
0 5 10 15 20
Days  after injection
Bo
dy
 w
ei
gh
t (
g)
B
od
y 
w
ei
gh
t (
g)
-0.5
0.0
0.5
1.0
1.5
2.0
2.5
day 7 14 21
*
In
su
lin
 (n
g/
m
L)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Lenti-
NS
Lenti-
shSREBP2
*
H
A B
D EC
F
G
N
or
ep
in
ep
hr
in
e
(n
g/
m
L)
0
2
4
6
8
10
12
14
16
Lenti-
NS
Lenti-
shSREBP2
**
Cholesterologenic
genes
Figure 7. SREBP-2 Knockdown in the Hypothalamus Affects Feeding Behavior and Metabolic Phenotype
(A) Western blots of ventral hypothalami from mice with intrahypothalamic (ihp) lentivirus injection on day 31.
(B) Confocal images of the lentivirus-infected hypothalami on day 7. In the left panel, red represents a neuronal marker MAP2, green derives from GFP that the
vectors encode, and blue represents nuclei. On the right, red represents the astrocyte marker GFAP. Arrows indicate the GFP-positive astrocyte processes.
Scale bar, 25 mm.
(C) Food intake of male C57Bl/6 mice after ihp injection of Lenti-shSREBP2 (n = 18) or control Lenti-NS (n = 19). Food intake was measured twice a day from day
15 after the injection for consecutive 12 days.
(D and E) Body weight change and absolute body weight of the same mice.
(F) Plasma norepinephrine concentrations in mice with ihp injection of Lenti-NS (n = 10) and Lenti-shSREBP2 (n = 10) after 48 hr of fasting.
(G) Fasting plasma insulin concentrations (24 hr) in mice with ihp injection of Lenti-NS (n = 10) and Lenti-shSREBP2 (n = 10). *p < 0.05; **p < 0.01 by t test. Error
bars represent SEM.
(H) Proposedmodel for cerebral dysfunction in diabetes via insulin-mediated cholesterol regulation. Reduction in circulating insulin results in reduced SREBP-2 in
both neurons and astroglial cells, and this results in a reduction of cholesterol synthesis and this causes changes in synapse components, affecting neural excit-
ability and functions.
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Insulin Regulates Brain Cholesterol MetabolismThese two cell types do appear to differ in response to hypergly-
cemia in vitro, with the effect of high glucose to lower cholester-
ologenic gene expression being greatest in glial cells. However,
reduction of hyperglycemia by phlorizin treatment in vivo does
not reverse the downregulation of cholesterologenic genes in
the diabetic mouse hypothalamus, whereas ICV insulin injection
does, indicating the dominant role of insulin in this regulatory
process. Our data indicate that multiple molecular pathways
are involved, including the mTORC1, PI 3-kinase, and MAP-
kinase pathways. These are also downstream of brain-derived
neurotrophic factor (Chen et al., 2009; Xia et al., 2010), which
has been shown to induce cholesterol synthesis and synapse
development in primary cultured neurons (Suzuki et al., 2007).
Insulin action on GSK3b and other pathways has also been
shown to play a role in controlling Tau phosphorylation in the
CNS (Lucas et al., 2001; Schubert et al., 2004) and neural
progenitor homeostasis (Kim et al., 2009).
Exactly what the full range of effects of reduced cholesterol
synthesis in brain in diabetes might be will need further study.
In addition to its role in myelin, cholesterol is an important
component of cell membranes and has been implicated in regu-
lation of the synaptophysin/synaptobrevin (VAMP) interaction
(Mitter et al., 2003) and geranylgeraniol production (Kotti et al.,
2006). We find that reduction in SREBP-2 in the hypothalamus
affects feeding behavior and circulating levels of the counterin-
sulin hormones norepinephrine and glucagon. This mixture of
hyperphagia with reduced plasma catecholamine levels is
similar to that observed in mice lacking synaptic vesicular trans-
porters for glutamate in VMH neurons (Tong et al., 2007). While
understanding the role of altered cholesterol biosynthesis in
diseases of the brain is still limited (Stefani and Liguri, 2009),
reduction of cholesterol biosynthesis has been observed in
a Huntington’s disease model (Valenza et al., 2005), whereas
prion infection has been shown to upregulate SREBP-2 and
cholesterol biosynthesis in cultured neurons (Bach et al.,
2009). Diabetes is a complex disease that may affect brain/
neuronal function by multiple mechanisms, in addition to its
effects on cholesterol metabolism.
Over the past decade there have been important advances in
defining the mechanisms that cells use to regulate cholesterol
levels and lipid metabolism (Horton et al., 2002). In liver and
kidney, insulin has been shown to activate both SREBP-1 and
SREBP-2 (Arito et al., 2008; Xie et al., 2009), which in turn control
both fatty acid and cholesterol biosynthesis. Our results indicate
that this same system plays an important role in control of brain
cholesterol levels with direct regulation by insulin of SREBP-2
and downstream cholesterologenic genes at the transcriptional
level leading to altered rates of cholesterol biosynthesis. This
results in a strong positive correlation between expression of
these cholesterologenic genes and cholesterol content in synap-
tosomal membranes in both human and mouse brain. In liver,
there is a strong feedback system in which cholesterol and sterol
intermediates regulate the activation of the SREBP family of tran-
scription factors through mechanisms involving ER-to-Golgi
transport and production of the active transcription factor
through limited proteolysis (Horton et al., 2002). While it is likely
that this feedback system is active in brain, in the brain of dia-
betic animals, there is a failure to compensate for reduced
cholesterol synthesis and reduced synaptosomal cholesterol576 Cell Metabolism 12, 567–579, December 1, 2010 ª2010 Elsevierwith upregulation of cholesterologenic genes. This might be
due to morphological complexity of neurons and astrocytes
that have long processes spatially distant from the endoplasmic
reticulum, where SREBP cleavage-activating protein (SCAP)
works as a sensor, or might represent a fundamental difference
in regulation of cholesterol synthesis in brain and liver.
An important question that this study does not address is how
therapy with statins (HMGCR inhibitors) might alter brain func-
tion in normal individuals or patients with diabetes or dementia.
Some studies have reported relatively acute cognitive decline
and memory loss in individuals on statins, which improve after
discontinuation of the drug (Evans and Golomb, 2009; Tuccori
et al., 2008; Xiong et al., 2005). On the other hand, larger
prospective trials assessing cognitive function in patients on sta-
tins have found no evidence of progression or protection from
cognitive decline (Trompet et al., 2010), and studies of statins
in patients with Alzheimer’s disease have shown no clear effects
to either protect or accelerate dementia (Shobab et al., 2005).
In summary, we have demonstrated that diabetes results in
broad alterations in expression of SREBP-2 and downstream
cholesterol synthetic genes in brain. This results in a reduction
of brain cholesterol synthesis, reduction in cholesterol precur-
sors, reduction in synaptosomal membrane cholesterol, and
changes in synaptic formation and function. In the hypothal-
amus, reducing SREBP-2-mediated cholesterol synthesis can
affect feeding behavior and control of endocrine function. This
dysregulation of brain cholesterol metabolism provides a novel
mechanism of altered brain and neuronal function observed in
diabetes and metabolic disorders. Alterations in brain choles-
terol metabolism could serve as a link between insulin, diabetes,
aging and a variety of disorders of neural function, including
effects on learning, memory and higher cognitive functions.
EXPERIMENTAL PROCEDURES
Animals
C57Bl/6, ob/ob (C57Bl/6 background), db/+, and db/db (C57Bl/Ks back-
ground) mice were from Jackson laboratory (Bar Harbor, ME). NIRKO mice
were generated as previously described (Bru¨ning et al., 2000). NOD mice
were provided by Diane Mathis and Wenyu Jiang (Harvard Medical School).
All mice used for experiments were male. For STZ-induced diabetes and
systemic insulin therapy experiments, 7-week-old C57Bl/6 mice were treated
with a single intraperitoneal (i.p.) injection (200 mg/g body weight) of STZ
(Sigma). After 2 days, the mice were separated into two groups. Half remained
untreated, and the other half were treated with subcutaneous insulin pellets
(LinShin, Toronto, Canada) for 1 week to control blood glucose levels. For
phlorizin (PHZ) treatment, 8-week-old C57Bl/6 mice were treated with STZ.
PHZ (Sigma) was dissolved in a solution containing 10% ethanol, 15%
DMSO, and 75% saline and was injected subcutaneously (0.4 g/kg) twice daily
for 10 days starting 8 days after the STZ injection. Control mice were injected
with the same volume of vehicle.
Mice were anesthesized with a 2.5% solution of 2:1 mixture of 2,2,2-tribro-
moethanol and tertiary amyl alcohol (15 ml/g body weight, i.p.). The brain was
quickly removed, placed on ice, and dissected using amouse brain matrix (ASI
Instruments Inc; Warren, MI). All animal studies followed National Institutes of
Health guidelines and were approved by the Institutional Animal Care and Use
Committees at the Joslin Diabetes Center.
Insulin ICV Injection in Diabetic Mice
Seven-week-old C57Bl/6 mice were placed in a stereotactic device under
anesthesia, and a 26-gauge guide cannula (Plastics One Inc.; Roanoke, VA)
was inserted into the right lateral cerebral ventricle (1.0 mm posterior,
1.0 mm lateral, and 2.0 mm ventral to the bregma). A dummy stylet cannulaInc.
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received a single i.p. injection of STZ to induce diabetes. Twelve days later,
the mice received three ICV injections of insulin (3 mU in 2 mL) or the same
volume of PBS (9 A.M., 7 P.M., and 9 A.M. the following day) through an
internal cannula using a Hamilton microsyringe. Food intake was measured
immediately before the ICV injection. Four hours after the last injection, blood
glucose levels were measured, and the hypothalami collected.
In Vivo Cholesterol Synthesis in the Brain
The rates of cholesterol synthesis in the brain were measured in 7-week-old
C57Bl/6 male mice 17 days after STZ or control buffer i.p. injection. Each
animal was injected i.p. with 50 mCi of [3H]water in 0.2 ml of PBS. One hour
later, each animal was anesthetized, blood was collected by retro-orbital
puncture, and the [3H]water-specific activity in the plasma was measured.
The brain was removed, and the whole cerebrum was saponified with 2.5 ml
of 2.5 M KOH (75C, 2 hr). Sterol-containing lipid was extracted using 10 ml
hexane and 5 ml 80% ethanol. Cholesterol was isolated by thin layer chroma-
tography (hexane: diethyl ether: glacial acetic acid = 80:20:1), and the incorpo-
rated tracer was measured by scintillation counting. Synthesis rates were
calculated as nmol of [3H]water incorporated into cholesterol per gram of
tissue per hour.
Synaptosomes were isolated using discontinuous sucrose density gradient
centrifugation (Kolomiytseva et al., 2008) as detailed in Supplemental Experi-
mental Procedures.
Measurement of Sterols in the Brain
Contents of cholesterol precursors and derivatives were measured in the
brains from 10-week-old C57Bl/6 mice, 18 days after STZ or control buffer
i.p. injection. Lipids were extracted from the sagitally sectioned half brains.
Sterols were resolved by HPLC, identified by a 4000 QTRAP mass spectrom-
eter (Applied Biosystems), and quantified by comparison of the areas under
the elution curves derived from the detection of endogenous compounds
and isotopically labeled standards (McDonald et al., 2007).
Primary Culture Glia and Cortical Neurons for Insulin and Glucose
Stimulation
The cerebral cortex was dissected from 0- to 1-day-old for glia and day 16
embryonic C57Bl/6 mice for neurons (see Supplemental Experimental Proce-
dures). For insulin stimulation, cells were serum deprived and preincubated
with medium containing 0.5% bovine serum albumin (BSA) for 6 hr, then stim-
ulated with 0 to 100 nM insulin for 6 hr. For glucose challenge, cells were incu-
bated in medium containing serum and 5mMor 25mMglucose for 72 hr. Cells
were harvested between 18 and 22 days after the initial plating.
Lentivirus Vector for SREBP-2 Silencing
Lentiviral vector plasmids for murine SREBP-2 shRNA (GIPZ Lentiviral shRNA-
mir, Open Biosystems; Huntsville, AL) and control nonsilencing (NS) shRNA
were packaged by cotransfection with packaging plasmids in HEK293T cells
(Trans-Lentiviral Packaging System, Open Biosystems). Viral particles were
concentrated by ultracentrifugation.
Primary Cultured Mouse Hippocampal Neurons
for Lentivirus-Mediated SREBP-2 Silencing
For confocal assays, primary cultures of hippocampus were prepared from
0- to 1-day-old C57Bl/6 mice using a Papain Dissociation System (Worthing-
ton Biomedical Corporation; Lakewood, NJ). Dissociated cells were plated on
poly-L-lysine-coated cover glasses (Carolina Biological Supply; Burlington,
NC) at 63 104 cells/cm2 and cultured in Neurobasal medium (Invitrogen) con-
taining the 13 B27 supplement (Invitrogen), 125 mMGlutaMax (Invitrogen) and
25 mMglutamic acid. Neurons were infected with lentivirus vectors after 2 days
in vitro (DIV). On 4 DIV the culture medium was changed to Neurobasal
medium supplemented with 13 B27, 125 mM GlutaMax and 10 mM cytosine
arabinoside (Sigma).
Intrahypothalamic Injection of Lentivirus Vectors
Seven- to eight-week-old male C57Bl/6 mice were used. The mice were
housed in individual cages, and given diet pellets containing 10% fat by kilo-
calories (D12450B, Research Diet, Inc.) and free access to water prior to theCell Mexperiments. The mice were placed in a stereotactic device under anesthesia,
and a 33-gauge cannula (Plastics One, Inc.) was inserted into the hypothal-
amus (0.5 mm posterior, ± 0.5 mm lateral, and 5.7 mm ventral from the
bregma). Lentivirus vector (108 TU/mL, 0.5 mL) was injected into the ventral
hypothalamus bilaterally between 9 and 10 A.M. Body weight of all mice
was monitored daily, and food intake was measured twice a day at
9–10 A.M. and 6–7 P.M., from 15 days after the injection for consecutive
12 days. Plasma norepinephrine levels were measured using an ELISA kit
(Immuno-Biological Laboratories, Inc.; Minneapolis, MN).
Statistical Analysis
Data are expressed as themean ±SEM. Statistical significancewas calculated
using an unpaired Student’s t test for comparison between two groups, and by
an analysis of variance (ANOVA) for multigroup comparison. Statistical signif-
icance in Pearson’s correlation coefficient (r) was determined by F-test.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
online at doi:10.1016/j.cmet.2010.11.006.
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